Home Ribo Bio Inks Over RMB 700 Million Deal with Qilu Pharma for PCSK9 siRNA Candidate RBD7022 in Greater China

Ribo Bio Inks Over RMB 700 Million Deal with Qilu Pharma for PCSK9 siRNA Candidate RBD7022 in Greater China

Mar 08, 2024 07:31 CST Updated 07:31
Ribo Life Science

Small Nucleic Acid Drug Developer

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer